SYRE: Spyre Therapeutics Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Spyre Therapeutics Inc (SYRE).
$1.20B Market Cap.
SYRE Market Cap. (MRY)
SYRE Shares Outstanding (MRY)
SYRE Assets (MRY)
Total Assets
$608.48M
Total Liabilities
$90.68M
Total Investments
$513.66M
SYRE Income (MRY)
Revenue
$0
Net Income
-$208.02M
Operating Expense
$208.57M
SYRE Cash Flow (MRY)
CF Operations
-$157.41M
CF Investing
-$353.29M
CF Financing
$410.91M
SYRE Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $608,484,000 (77.99%) | $341,859,000 (380.52%) | $71,144,000 (-35.28%) | $109,926,000 (-31.98%) |
Assets Current | $608,474,000 (78.16%) | $341,528,000 (448.57%) | $62,258,000 (-37.04%) | $98,891,000 (-33.98%) |
Assets Non-Current | $10,000 (-96.98%) | $331,000 (-96.28%) | $8,886,000 (-19.47%) | $11,035,000 (-6.71%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $517,804,000 (181.39%) | $184,016,000 (265.80%) | $50,305,000 (-40.07%) | $83,941,000 (-39.97%) |
Property Plant & Equipment Net | $0 (0%) | $0 (0%) | $6,650,000 (-20.41%) | $8,355,000 (-15.37%) |
Cash & Equivalents | $89,423,000 (-52.74%) | $189,215,000 (419.59%) | $36,416,000 (114.46%) | $16,980,000 (-81.53%) |
Accumulated Other Comprehensive Income | $180,000 (-40.40%) | $302,000 (729.17%) | -$48,000 (-140.00%) | -$20,000 (-281.82%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $2,696,000 (-24.61%) | $3,576,000 (0%) |
Total Investments | $513,665,000 (241.57%) | $150,384,000 (621.34%) | $20,848,000 (-73.27%) | $77,986,000 (38.82%) |
Investments Current | $513,665,000 (241.57%) | $150,384,000 (621.34%) | $20,848,000 (-73.27%) | $77,986,000 (38.82%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $375,000 (-53.99%) | $815,000 (0%) |
Trade & Non-Trade Payables | $1,269,000 (-92.74%) | $17,480,000 (2481.98%) | $677,000 (-79.60%) | $3,319,000 (47.25%) |
Accumulated Retained Earnings (Deficit) | -$972,432,000 (-27.21%) | -$764,414,000 (-79.60%) | -$425,624,000 (-24.52%) | -$341,809,000 (-23.84%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $0 (0%) | $0 (0%) | $4,629,000 (-8.23%) | $5,044,000 (-7.42%) |
Debt Current | $0 (0%) | $0 (0%) | $625,000 (43.35%) | $436,000 (36.68%) |
Debt Non-Current | $0 (0%) | $0 (0%) | $4,004,000 (-13.11%) | $4,608,000 (-10.16%) |
Total Liabilities | $90,680,000 (23.73%) | $73,288,000 (251.69%) | $20,839,000 (-19.80%) | $25,985,000 (19.27%) |
Liabilities Current | $54,060,000 (69.05%) | $31,978,000 (118.19%) | $14,656,000 (-27.24%) | $20,144,000 (22.51%) |
Liabilities Non-Current | $36,620,000 (-11.35%) | $41,310,000 (568.12%) | $6,183,000 (5.86%) | $5,841,000 (9.32%) |
SYRE Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $0 (0%) | $886,000 (-61.96%) | $2,329,000 (-87.57%) | $18,739,000 (0%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $45,776,000 (14.59%) | $39,946,000 (40.01%) | $28,531,000 (4.44%) | $27,319,000 (25.07%) |
Research & Development Expense | $162,790,000 (81.88%) | $89,504,000 (52.79%) | $58,579,000 (2.65%) | $57,069,000 (-4.31%) |
Operating Expenses | $208,566,000 (-14.24%) | $243,189,000 (179.17%) | $87,110,000 (3.23%) | $84,388,000 (3.57%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $51,000 (296.15%) | -$26,000 (80.88%) | -$136,000 (-196.45%) | $141,000 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$208,018,000 (38.60%) | -$338,790,000 (-304.21%) | -$83,815,000 (-27.38%) | -$65,801,000 (18.66%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$208,018,000 (38.60%) | -$338,790,000 (-304.21%) | -$83,815,000 (-27.38%) | -$65,801,000 (18.66%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$208,018,000 (38.60%) | -$338,790,000 (-304.21%) | -$83,815,000 (-27.38%) | -$65,801,000 (18.66%) |
Weighted Average Shares | $47,027,638 (581.85%) | $6,897,065 (104.59%) | $3,371,231 (28.19%) | $2,629,784 (23.18%) |
Weighted Average Shares Diluted | $47,027,638 (581.85%) | $6,897,065 (104.59%) | $3,371,231 (28.19%) | $2,629,784 (23.18%) |
Earning Before Interest & Taxes (EBIT) | -$207,967,000 (38.62%) | -$338,816,000 (-303.59%) | -$83,951,000 (-27.86%) | -$65,660,000 (18.83%) |
Gross Profit | $0 (0%) | $886,000 (-61.96%) | $2,329,000 (-87.57%) | $18,739,000 (0%) |
Operating Income | -$208,566,000 (13.92%) | -$242,303,000 (-185.80%) | -$84,781,000 (-29.14%) | -$65,649,000 (19.43%) |
SYRE Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$353,285,000 (-225.93%) | -$108,393,000 (-290.14%) | $57,008,000 (352.04%) | -$22,619,000 (-197.46%) |
Net Cash Flow from Financing | $410,906,000 (13.80%) | $361,077,000 (746.05%) | $42,678,000 (2963.75%) | $1,393,000 (-99.10%) |
Net Cash Flow from Operations | -$157,410,000 (-57.55%) | -$99,910,000 (-24.66%) | -$80,144,000 (-49.20%) | -$53,716,000 (29.11%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$99,792,000 (-165.31%) | $152,799,000 (686.16%) | $19,436,000 (125.93%) | -$74,957,000 (-205.30%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $18,035,000 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | -$353,285,000 (-178.39%) | -$126,903,000 (-322.46%) | $57,046,000 (358.76%) | -$22,046,000 (-563.24%) |
Capital Expenditure | $0 (0%) | $475,000 (1350.00%) | -$38,000 (93.37%) | -$573,000 (86.61%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | -$16,000 (96.17%) | -$418,000 (18.04%) | -$510,000 (-2450.00%) |
Issuance (Purchase) of Equity Shares | $243,893,000 (187.07%) | $84,960,000 (97.14%) | $43,096,000 (2164.63%) | $1,903,000 (-98.77%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | -$3,000 (-112.00%) | $25,000 (123.58%) | -$106,000 (-606.67%) | -$15,000 (-129.41%) |
Share Based Compensation | $44,833,000 (74.62%) | $25,675,000 (261.06%) | $7,111,000 (-11.53%) | $8,038,000 (28.48%) |
Depreciation Amortization & Accretion | $0 (0%) | $964,000 (-50.92%) | $1,964,000 (-1.85%) | $2,001,000 (23.21%) |
SYRE Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | - | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% |
Profit Margin | - | -38238.10% (-962.52%) | -3598.80% (-925.01%) | -351.10% |
EBITDA Margin | - | -38132.30% (-983.21%) | -3520.30% (-936.30%) | -339.70% |
Return on Average Equity (ROAE) | -60.70% (-110.53%) | 576.40% (553.50%) | -127.10% (-107.00%) | -61.40% (10.63%) |
Return on Average Assets (ROAA) | -42.60% (73.44%) | -160.40% (-68.66%) | -95.10% (-98.54%) | -47.90% (17.84%) |
Return on Sales (ROS) | - | -38241.10% (-960.90%) | -3604.60% (-928.71%) | -350.40% |
Return on Invested Capital (ROIC) | -62.00% (-101.02%) | 6106.20% (3273.70%) | -192.40% (-130.42%) | -83.50% (27.01%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -7.32 (-368.09%) | -1.56 (-246.02%) | -0.45 (90.48%) | -4.75 (8.34%) |
Price to Sales Ratio (P/S) | - | 167.52 (928.94%) | 16.28 (-2.30%) | 16.66 |
Price to Book Ratio (P/B) | 2.31 (387.76%) | 0.47 (-13.82%) | 0.55 (-80.29%) | 2.79 (3.45%) |
Debt to Equity Ratio (D/E) | 0.17 (-56.03%) | 0.4 (-3.86%) | 0.41 (33.55%) | 0.31 (98.72%) |
Earnings Per Share (EPS) | -3.18 (76.89%) | -13.76 (44.65%) | -24.86 (0.64%) | -25.02 (34.16%) |
Sales Per Share (SPS) | 0 (0%) | 0.13 (-81.48%) | 0.69 (-90.30%) | 7.13 (0%) |
Free Cash Flow Per Share (FCFPS) | -3.35 (76.78%) | -14.42 (39.38%) | -23.78 (-15.21%) | -20.64 (44.95%) |
Book Value Per Share (BVPS) | 11.01 (-58.73%) | 26.68 (78.80%) | 14.92 (-53.25%) | 31.92 (-51.27%) |
Tangible Assets Book Value Per Share (TABVPS) | 12.94 (-73.90%) | 49.57 (134.88%) | 21.1 (-49.51%) | 41.8 (-44.78%) |
Enterprise Value Over EBIT (EV/EBIT) | -5 (0%) | 0 (0%) | 0 (0%) | -3 (25.00%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -5.41 (-38764.29%) | 0.01 (-85.86%) | 0.1 (102.96%) | -3.35 (18.87%) |
Asset Turnover | 0 (0%) | 0 (-84.62%) | 0.03 (-80.88%) | 0.14 (0%) |
Current Ratio | 11.26 (5.39%) | 10.68 (151.41%) | 4.25 (-13.47%) | 4.91 (-46.11%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$157,410,000 (-58.30%) | -$99,435,000 (-24.01%) | -$80,182,000 (-47.69%) | -$54,289,000 (32.19%) |
Enterprise Value (EV) | $1,125,738,802 (23719.75%) | -$4,766,091 (41.15%) | -$8,098,166 (-103.80%) | $212,928,800 (-34.85%) |
Earnings Before Tax (EBT) | -$207,967,000 (38.62%) | -$338,816,000 (-303.59%) | -$83,951,000 (-27.86%) | -$65,660,000 (18.83%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$207,967,000 (38.44%) | -$337,852,000 (-312.08%) | -$81,987,000 (-28.79%) | -$63,659,000 (19.69%) |
Invested Capital | $465,001,000 (285.36%) | $120,666,000 (388.51%) | $24,701,000 (-68.27%) | $77,846,000 (32.65%) |
Working Capital | $554,414,000 (79.10%) | $309,550,000 (550.29%) | $47,602,000 (-39.55%) | $78,747,000 (-40.95%) |
Tangible Asset Value | $608,484,000 (77.99%) | $341,859,000 (380.52%) | $71,144,000 (-35.28%) | $109,926,000 (-31.98%) |
Market Capitalization | $1,197,318,802 (1274.13%) | $87,132,909 (214.86%) | $27,673,834 (-88.19%) | $234,269,800 (-37.90%) |
Average Equity | $342,962,000 (683.51%) | -$58,775,750 (-189.16%) | $65,918,500 (-38.51%) | $107,200,250 (-8.99%) |
Average Assets | $488,310,500 (131.12%) | $211,276,500 (139.69%) | $88,146,750 (-35.84%) | $137,395,750 (-0.97%) |
Invested Capital Average | $335,591,000 (6148.05%) | -$5,548,750 (-112.72%) | $43,628,000 (-44.54%) | $78,672,250 (11.23%) |
Shares | 51,431,220 (1170.24%) | 4,048,927 (64.56%) | 2,460,443 (24.72%) | 1,972,798 (2.88%) |
